Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

conquest crop protection pty ltd - non-ionic alkoxylated alcohol; ammonium sulphate - soluble powder - non-ionic alkoxylated alcohol emulsifiers & surfactants noni active 100.0 g/kg; ammonium sulphate ammonium active 891.5 g/kg - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - improve performance | tank mixing | wetting agent (use as directed) | additive | agricultural chemical | herbicide | improve penetrating properties | minimise antagonism | spray tank | under adverse environmental co

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alfa laval pty ltd - non-ionic alkoxylate | sodium dichloroisocyanurate | sodium hydroxide - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; sodium hydroxide - liquid - non-ionic detergents emulsifiers & surfactants-noni active 6.0 g/l; sodium hydroxide mineral-sodium-base active 644.0 g/l - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

delaval pty ltd - chlorine present as sodium dichloroisocyanurate; sodium hydroxide - powder - chlorine present as sodium dichloroisocyanurate mineral-chlorine active 51.0 g/kg; sodium hydroxide mineral-sodium-base active 75.0 g/kg - dairy cleanser - milking equipment | milking machine - alkali detergent

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

delaval pty ltd - chlorine present as sodium dichloroisocyanurate; sodium hydroxide - powder - chlorine present as sodium dichloroisocyanurate mineral-chlorine active 38.0 g/kg; sodium hydroxide mineral-sodium-base active 586.0 g/kg - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

delaval pty ltd - chlorine present as sodium dichloroisocyanurate; sodium hydroxide - soluble powder - chlorine present as sodium dichloroisocyanurate mineral-chlorine active 38.0 g/kg; sodium hydroxide mineral-sodium-base active 586.0 g/kg - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ruakura pty limited - alkaline salts; chlorine present as sodium dichloroisocyanurate; sodium hydroxide - soluble powder - alkaline salts cleanser/sanitiser active 330.0 g/kg; chlorine present as sodium dichloroisocyanurate mineral-chlorine active 23.6 g/kg; sodium hydroxide mineral-sodium-base active 620.0 g/kg - dairy cleanser - dairy plant stainless steel | milking equipment | building | milking machine - milkstone removal | residue, dirt in milking equipment | milk fat | milk protein | mineral deposits

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride tablets are indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life

USA - engelsk - NLM (National Library of Medicine)

american health packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the f

USA - engelsk - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride tablets are indicated to: usage considerations: propafenone hydrochloride tablets are contraindicated in the following circumstances: risk summary there are no studies of propafenone hydrochloride tablets in pregnant women. available data from published case reports and several decades of postmarketing experience with use of propafenone hydrochloride tablets in pregnancy have not identified any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. untreated arrhythmias during pregnancy may pose a risk to the pregnant woman and fetus (see clinical considerations) . propafenone and its metabolite, 5-oh-propafenone, cross the placenta in humans. in animal studies, propafenone was not teratogenic. at maternally toxic doses (ranging from 2 to 6 times the maximum recommended human dose [mrhd]), there was evidence of adverse developmental outcomes when administered to pregnant rabbits and rats during organogenesis or when administered to pregnant rat